[Pharmacokinetic and clinical research of a new phenyl ester of carbecinillin: carfecillin].
Following a review of the latest methods of treating infections of the urinary ways, the pharmacokinetic and clinical results of a new antibiotic, Carfecillin, are reported. The examination was carried out on a total of 10 volunteers. The substance showed good serum levels and fair renal excretion with both the 250 mg and the 500 mg p.o. doses. The clinical study was carried out on a double blind basis versus a standard reference (indanyl ester of carbenicillin) in 26 patients and showed the electivity of the antibiotic in the oral treatment of urinary infections under well tolerated conditions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002228:Carbenicillin / Q000031:analogs & derivatives*; D002323:Carfecillin / Q000008:administration & dosage* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002323:Carfecillin; D002228:Carbenicillin
Ricerca farmacocinetica e clinica su un nuovo estere fenilico di carbenicillina: carfecillina.